ClinicalTrials.gg
TerminatedNCT05191862Updated Mar 13, 2025

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

A Phase 1 interventional study of Cilostazol 100 mg and PMR 135 mg in Intermittent Claudication, sponsored by Genovate Biotechnology Co., Ltd.,. Terminated at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Genovate Biotechnology Co., Ltd., · Phase 1, Interventional, and Treatment

Why this study was terminated
Randomization Error

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate-release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.

02

Conditions studied

  • Intermittent Claudication

Keywords

  • Peripheral Artery Disease
  • Cilostazol
  • PMR
  • Extended-Release Tablet of Cilostazol
03

In context

Intermittent Claudication

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

This study's enrollment of 19 is below the median of 74 across 242 interventional studies indexed under Intermittent Claudication.

Browse Intermittent Claudication studies →

Lead sponsor

Genovate Biotechnology Co., Ltd., is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18 to 45 years of age, inclusive, at screening.
  • Absence of diseases that could affect the study outcomes.
  • Having a (BMI) between 18.5 and 27.0, inclusive, at screening.
  • Females must have a negative serum pregnancy test at screening.
  • Understanding and willing to participate in the clinical study and able to comply with study procedures and visits.

Exclusion criteria

Exclusion Criteria:

  • History of bleeding tendency.
  • Use of anticoagulant agent(s) within one (1) month prior to screening.
  • Use of tobacco or nicotine products within six (6) months of screening.
  • Intake of over the counter (OTC) or prescription drugs (other than hormonal ) within two (2) weeks prior to randomization.
  • On any drug(s) or therapeutic device(s) within thirty (30) days preceding screening; or anticipating use of any of these therapies during the course of the study (other than the study products).
  • History of substance abuse, such as alcohol, IV drugs, and inhaled drugs, within one (1) year prior to screening.
  • Known history of having Acquired Immunodeficiency Syndrome (AIDS) or positive pre-study result of infection with (HIV); known history or positive pre-study surface antigen or positive antibody result within three (3) months of screening.
  • Positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at any time during the study, either asymptomatic or present with symptoms of Coronavirus disease 2019 (COVID-19).
  • Pregnant or breast feeding.
  • Women of not using an effective birth control method. Women of child-bearing potential are defined as women physiologically capable of becoming pregnant, UNLESS they meet the following criteria:

    1. : 12 months of natural (spontaneous) amenorrhea or less than twelve (12) months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40IU/L, OR;
    2. Six (6) weeks post-surgical bilateral oophorectomy with or without hysterectomy, OR;
    3. Are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g. bilateral tubal ligation, hysterectomy), hormonal contraception (e.g. implantable, injectable, vaginal, patch, and oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for seven (7) days after study discontinuation.
  • Known or suspected to any ingredient of the study drug(s).
  • Donated blood or lost more than 150 mL of blood within three (3) months prior to randomization or plans to donate blood or plasma within four (4) weeks after completion of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    Sequence 1

    Treatment RTRT

    Drug: Cilostazol 100 mg · Drug: PMR 135 mg

  • Other
    Sequence 2

    Treatment TRTR

    Drug: Cilostazol 100 mg · Drug: PMR 135 mg

Interventions

  • One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)

    Also known as: Treatment R

  • DrugPMR 135 mg

    Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)

    Also known as: Treatment T

06

What researchers measure

Primary outcomes

  1. Area under the curve, from time zero to last measureable time point (AUC 0-t )

    Time frame: 0-72 hours after morning dose

  2. AUC from time zero to infinity (AUC 0-∞)

    Time frame: 0-72 hours after morning dose

07

Study locations

1 site
  • Bio-Kinetic Clinical Applications, LLC
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 14, 2022
StartActual
Apr 23, 2022
Primary completionActual
May 4, 2022
CompletionActual
May 7, 2022
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05191862
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Apr 23, 2022
Primary completion
May 4, 2022
Completion
May 7, 2022
Last update
Mar 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion